Galapagos reports initiation of FALCON clinical trial in cystic fibrosis

                         
Mechelen, Belgium; 24 April 2018; 08.45 AM CET –Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of its first clinical trial with an investigational triple combination therapy in cystic fibrosis patients.